Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Giuseppe Barbesino"'
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 2, Pp 330-337 (2021)
Objective: To investigate and characterize the clinical and radiologic features of 10 patients with painful subacute thyroiditis with ultrasound findings considered suspicious for malignancy or for whom biopsy of a suspicious area was recommended by
Externí odkaz:
https://doaj.org/article/c630f90770224b0bb15e0cd4c4d88300
Autor:
Giuseppe Barbesino
Publikováno v:
Clinical Thyroidology. 35:205-207
Autor:
Giuseppe Barbesino
Publikováno v:
Clinical Thyroidology. 35:54-56
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 107:S47-S56
Background and Aims This review aims to summarize current and emerging therapies for treatment of thyroid eye disease (TED), in the light of novel understanding of pathogenetic mechanisms, leading to new treatment options and clinical trials. Methods
Publikováno v:
Journal of the Endocrine Society. 7
ContextThyroglobulin autoantibodies (TgAbs) affect thyroglobulin immunometric assays (TgIMAs), causing falsely low results. Conversely, heterophilic antibodies (HAs) may cause falsely elevated results. Thyroglobulin (Tg) measurements by mass spectrom
Publikováno v:
Endocrine Practice. 27:396-400
Objective To report a case series of thyroid cancer patients in whom false positive results in immunometric assays for thyroglobulin (TgIMA) were caused by heterophilic antibody interference, describe the clinical scenario in which this interference
Autor:
Giuseppe Barbesino
Publikováno v:
A Case-Based Guide to Clinical Endocrinology ISBN: 9783030843663
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ffabfec1dba98ed267fd9a56e9bb5ee
https://doi.org/10.1007/978-3-030-84367-0_9
https://doi.org/10.1007/978-3-030-84367-0_9
Autor:
Terry J Smith, Rajib K Bhattacharya, Kate Hsu, Sun Kim, Saba Sile, Giuseppe Barbesino, Robert Holt
Publikováno v:
Journal of the Endocrine Society. 6:A809-A809
Background Teprotumumab, an FDA-approved insulin-like growth factor-1 receptor inhibitor for TED, improves proptosis, diplopia, inflammation, and quality of life. In the pooled phase 2 and 3 trial analysis, 8/84 (10%) teprotumumab-treated patients re
Autor:
Raymond S, Douglas, Roger, Dailey, Prem S, Subramanian, Giuseppe, Barbesino, Shoaib, Ugradar, Ryan, Batten, Rana A, Qadeer, Chris, Cameron
Publikováno v:
JAMA Ophthalmology. 140:328
Thyroid eye disease can be a debilitating autoimmune disorder characterized by progressive proptosis or diplopia. Teprotumumab has been compared with placebo in randomized clinical trials, but not with intravenous methylprednisolone (IVMP), which som
Autor:
Terry F. Davies, Stig Andersen, Rauf Latif, Yuji Nagayama, Giuseppe Barbesino, Maria Brito, Anja K. Eckstein, Alex Stagnaro-Green, George J. Kahaly
Publikováno v:
Davies, T F, Andersen, S, Latif, R, Nagayama, Y, Barbesino, G, Brito, M, Eckstein, A K, Stagnaro-Green, A & Kahaly, G J 2020, ' Graves’ disease ', Nature Reviews. Disease Primers, vol. 6, no. 1, 52 . https://doi.org/10.1038/s41572-020-0184-y
Graves’ disease (GD) is an autoimmune disease that primarily affects the thyroid gland. It is the most common cause of hyperthyroidism and occurs at all ages but especially in women of reproductive age. Graves’ hyperthyroidism is caused by autoan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f99500a255e1c2d5f16bf775cdbda13b
https://vbn.aau.dk/da/publications/c978d403-25bf-4862-9a88-4c3b0e13dc66
https://vbn.aau.dk/da/publications/c978d403-25bf-4862-9a88-4c3b0e13dc66